Avantor (AVTR) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 revenue was $1.70 billion, with organic sales down 2%–2.4% year-over-year but sequential improvement in all key financial metrics.
Adjusted EBITDA margin expanded over 100 basis points sequentially to 17.9%, and adjusted EPS was $0.25, both above guidance.
Net income rebounded to $92.9 million from a loss last year, driven by the absence of impairment charges and lower interest expense.
Free cash flow was strong at $235 million for the quarter, with year-to-date free cash flow conversion exceeding 100%.
Cost transformation initiative is ahead of plan, targeting $300 million in annual gross run-rate savings by end of 2026.
Financial highlights
Adjusted gross profit was $572–$583 million (34.0%–34.2% margin); adjusted EBITDA was $305.6–$306 million (17.9% margin).
Adjusted operating income was $277.2 million (16.3% margin); adjusted EPS was $0.25.
Free cash flow for the quarter was $235 million; year-to-date free cash flow conversion exceeded 100%.
Adjusted net leverage ended the quarter at 3.9x adjusted EBITDA.
Net income margin was 5.5%; adjusted net income was $168 million (9.9% margin).
Outlook and guidance
Full-year 2024 guidance reaffirmed, with organic revenue growth expected between -2% and +1%.
Reported revenue guidance: $6.85B to $7.06B; adjusted EBITDA margin forecasted at 17.4%–17.9%.
Adjusted EPS guidance: $0.96–$1.04; free cash flow expected at $600M–$650M.
Cost transformation expected to deliver $300 million in annual savings by 2026, with $50–$65 million in restructuring charges.
Year-to-date margin performance has de-risked adjusted EBITDA margin and EPS guidance.
Latest events from Avantor
- Q3 2025 net loss of $711.8M on 5.3% lower sales; $500M buyback and cost actions announced.AVTR
Q3 202517 Mar 2026 - 2026 is a transition year with Revival investments, margin pressure, and strong free cash flow.AVTR
Q4 202511 Feb 2026 - Cost transformation and innovation drive margin expansion and resilience amid cautious demand.AVTR
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Cost transformation and bioprocessing momentum support a positive growth outlook.AVTR
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 2024 saw $1.71B revenue, strong cash flow, and raised FCF guidance amid cost transformation.AVTR
Q3 202418 Jan 2026 - Revival program and capital strategy accelerate transformation and global leadership.AVTR
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Bioprocessing and healthcare drive growth, with strong order trends and margin expansion into 2025.AVTR
7th Annual Evercore ISI HealthCONx Conference12 Jan 2026 - Robust growth, margin expansion, and innovation leadership drive strong financial outlook.AVTR
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Net sales fell 6% but net income rose, with $400M in cost savings targeted by 2027.AVTR
Q1 20256 Jan 2026